Synovial ultrasound as primary outcome in a 3-arm, randomized, open-label, parallel active controlled, multicenter international study comparing baricitinib, alone and combined with MTX versus TNF-alfa inhibitor in rheumatoid arthritis patients: Searching for synovium predictors of response.
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Baricitinib (Primary) ; Etanercept; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms BIOP-US
Most Recent Events
- 30 Nov 2023 This trial has been discontinued in Denmark according to European Clinical Trials Database record.
- 31 May 2019 New trial record